Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
A prospective, single-arm, open-label phase 2 study that evaluates the efficacy and safety of
induction Lorlatinib in stage III non-small cell lung cancer and explores the clinical
feasibility of dynamic ctDNA and multidisciplinary assessment in guiding local treatments.